Ceribell, Inc. (NASDAQ:CBLL) saw recent insider activity as Chief Technology Officer Raymond Woo disposed of 11,104 shares of common stock on May 1, 2026. The total value realized from these sales was $226,928, with the individual share prices ranging between $19.88 and $20.64.
Detailed Transaction Breakdown
The disposal of shares was facilitated by the exercise of various stock options. Mr. Woo acquired the 11,104 shares at costs ranging from $2.24 to $4.70 per share, representing a total acquisition expenditure of $48,575. The specific breakdown of these exercises and subsequent sales is as follows:
- First Tranche: 1,469 shares were exercised at $2.24 each and subsequently sold at a weighted average price of $20.39 per share.
- Second Tranche: 3,024 shares were exercised at $4.70 each and subsequently sold at a weighted average price of $20.43 per share.
- Third Tranche: 6,611 shares were exercised at $4.70 each and subsequently sold at a weighted average price of $20.45 per share.
The options involved in these transactions included some that were fully vested and immediately exercisable, as well as others subject to monthly vesting. Specifically, certain portions vested at a rate of 1/48 of the shares on each monthly anniversary of April 1, 2023, contingent upon continued employment with the company.
Market Context and Valuation
These transactions occurred while Ceribell's stock was trading near $20.27, a level that follows an 86% increase in share value over the previous six months. The company currently holds a market capitalization of $776 million. However, analysis suggests that the stock may be appearing overvalued relative to its calculated Fair Value.
Regulatory and Analyst Developments
In addition to the insider trading activity, Ceribell is navigating developments within the healthcare technology sector. The Centers for Medicare & Medicaid Services (CMS) has submitted a proposal for a new technology add-on payment (NTAP). This proposal suggests an add-on payment of up to $2,171 for the company's delirium monitoring system. To provide perspective, this proposed amount is more than double the payment previously received by the company for its status epilepticus NTAP, which began in fiscal year 2024.
From an analyst standpoint, TD Cowen has maintained a Buy rating on Ceribell, setting a price target of $29.00. These factors, including the potential CMS payment, could impact the financial performance of the delirium monitoring system and reflect the company's position in the healthcare technology market.